Company: INmune Bio, Inc.
Job title: CSO
Arming Cell Therapies to Override Immunosuppressive Mechanisms & Penetrate Tumours 9:00 am
Priming patients NK cells with INKmune to initiate successful homing to the tumour microenvironment and elimination of cancer cells Reviewing preclinical data of “pseudokine” activity producing the same proteomic effects of combinations of IL12/15/18 Leveraging clinical data of the clinical responses of “pseudokine” to determine its safety and efficacyRead more
day: Day One